p300/MDM2 complexes participate in MDM2-mediated p53 degradation

Molecular Cell

Volumn 2, Issue 4, 1998, Pages 405-415

  Grossman, Steven R ^a   Perez, Marco ^a   Kung, Andrew L ^a   Joseph, Michael ^a   Mansur, Claire ^b   Xiao, Zhi Xiong ^c   Kumar, Sushant ^a   Howley, Peter M ^a   Livingston, David M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; TRANSACTIVATOR PROTEIN; TUMOR PROTEIN; UBIQUITIN;

ARTICLE; CELL LINE; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTAGENESIS; PHYSIOLOGY; PROTEIN BINDING; SEQUENCE HOMOLOGY;

CELL LINE; DNA-BINDING PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, VIRAL; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SEQUENCE HOMOLOGY, AMINO ACID; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINS;

EID: 0032185124     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(00)80140-9     Document Type: Article

References (57)

1. Arany, Z., Huang, L.E., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M.A., Bunn, H.F., and Livingston, D.M. (1996). An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA 93, 12969-12973.
2. Avantaggiati, M.L., Carbone, M., Graessmann, A., Nakatani, Y., Howard, B., and Levine, A.S. (1996).The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional coactivator, p300. EMBO J. 15, 2236-2248.
3. Avantaggiati, M.L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A.S., and Kelly, K. (1997). Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89, 1175-1184.
4. Beer-Romero, P., Glass, S., and Rolfe, M. (1997). Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene 14, 595-602.
5. Bottger, A., Bottger, V., Sparks, A., Liu, W.L., Howard, S.F., and Lane, D.P. (1997). Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7, 860-869.
6. Chen, C., and Okayama, H. (1987). High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7, 2745-2752.
7. Chen, J., Marechal, V., and Levine, A.J. (1993). Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13, 4107-4114.
8. Chen, J., Lin, J., and Levine, A.J. (1995). Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1, 142-152.
9. Chen, J., Wu, X., Lin, J., and Levine, A.J. (1996). Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16, 2445-2452.
10. Chiou, S.K., and White, E. (1997). p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. J. Virol. 71, 3515-3525.
11. Crook, T., and Vousden, K.H. (1992). Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J. 11, 3935-3940.
12. Eckner, R., Ewen, M.E., Newsome, D., Gerdes, M., DeCaprio, J.A., Lawrence, J.B., and Livingston, D.M. (1994). Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 8, 869-884.
13. Eckner, R., Ludlow, J.W., Lill, N.L., Oldread, E., Arany, Z., Modjtahedi, N., DeCaprio, J.A., Livingston, D.M., and Morgan, J.A. (1996). Association of p300 and CBP with simian virus 40 large T antigen. Mol. Cell. Biol. 16, 3454-3464.
14. Gu, W., and Roeder, R.G. (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606.
15. Gu, W., Shi, X.L., and Roeder, R.G. (1997). Synergistic activation of transcription by CBP and p53. Nature 387, 819-823.
16. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
17. Hershko, A. (1997). Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr. Opin. Cell Biol. 9, 788-799.
18. Honda, R., Tanaka, H., and Yasuda, H. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27.
19. Horvai, A.E., Xu, L., Korzus, E., Brard, G., Kalafus, D., Mullen, T.M., Rose, D.W., Rosenfeld, M.G., and Glass, C.K. (1997). Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc. Natl. Acad. Sci. USA 94, 1074-1079.
20. Huibregtse, J.M., Scheffner, M., and Howley, P.M. (1993). Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell. Biol. 13, 775-784.
21. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R.A., Rose, D.W., Glass, C.K., and Rosenfeld, M.G. (1996). A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85, 403-414.
22. Ko, L.J., and Prives, C. (1996). p53: puzzle and paradigm. Genes Dev. 10, 1054-1072.
23. Korzus, E., Torchia, J., Rose, D.W., Xu, L., Kurokawa, R., McInerney, E.M., Mullen, T.M., Glass, C.K., and Rosenfeld, M.G. (1998). Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 279, 703-707.
24. Kubbutat, M.H.G., Jones, S.N., and Vousden, K.H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
25. Lechner, M.S., and Laimins, L.A. (1994). Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 68, 4262-4273.
26. Levine, A.J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
27. Lill, N.L., Grossman, S.R., Ginsberg, D., DeCaprio, J.A., and Livingston, D.M. (1997a). Binding and modulation of p53 by p300/CBP coactivators. Nature 387, 823-827.
28. Lill, N.L., Tevethia, M.J., Eckner, R., Livingston, D.M., and Modjtahedi, N. (1997b). p300 family members associate with the carboxyl terminus of simian virus 40 large tumor antigen. J. Virol. 71, 129-137.
29. Lin, J., Chen, J., Elenbaas, B., and Levine, A.J. (1994). Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246.
30. Lowe, S.W., and Ruley, H.E. (1993). Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 7, 535-545.
31. Maki, C.G., and Howley, P.M. (1997). Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol. 17, 355-363.
32. Maki, C.G., Huibregtse, J.M., and Howley, P.M. (1996). In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56, 2649-2654.
33. Mansur, C.P., Marcus, B., Dalal, S., and Androphy, E.J. (1995). The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene 10, 457-465.
34. Momand, J., and Zambetti, G.P. (1996). Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 12, 2279-2289.
35. Momand, J., Zambetti, G.P., Olson, D.C., George, D., and Levine, A.J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245.
36. Mummenbrauer, T., Janus, F., Müller, B., Wiesmüller, L., Deppert, W., and Grosse, F. (1996). p53 protein exhibits 3′-to-5′ exonuclease activity. Cell 85, 1089-1099.
37. Ogryzko, V.V., Schiltz, R.L., Russanova, V., Howard, B.H., and Nakatani, Y. (1996). The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87, 953-959.
38. Oliner, J.D., Pietenpol, J.A., Thiagalingam, S., Gyuris, J., Kinzler, K.W., and Vogelstein, B. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860.
39. Pollard, V.W., Harris, M.E., and Hajduk, S.L. (1992). Native mRNA editing complexes from Trypanosoma brucei mitochondria. EMBO J. 11, 4429-4438.
40. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723.
41. Querido, E., Teodora, J.G., and Branton, P.E. (1997). Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis. J. Virol. 71, 3526-3533.
42. Reihsaus, E., Kohler, M., Kraiss, S., Oren, M., and Montenarh, M. (1990). Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene 5, 137-145.
43. Roth, J., Dobbelstein, M., Freedman, D.A., Shenk, T., and Levine, A.J. (1998). Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17, 554-564.
44. Sanchez-Prieto, R., Lleonart, M., and Ramon y Cajal, S. (1995). Lack of correlation between p53 level and sensitivity to DNA-damaging agents in keratinocytes carrying adenovirus E1A mutants. Oncogene 11, 675-682.
45. Sarnow, P., Ho, Y.S., Williams, J., and Levine, A.J. (1982). Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28, 387-394.
46. Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J., and Howley, P.M. (1990). The E6 oncoprotein encoded by human papillo-mavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.
47. Scheffner, M., Huibregtse, J.M., Vierstra, R.D., and Howley, P.M. (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505.
48. Scolnick, D.M., Chehab, N.H., Stavridi, E.S., Lien, M.C., Caruso, L., Moran, E., Berger, S.L., and Halazonetis, T.D. (1997). CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 57, 3693-3696.
49. Somasundaram, K., and El-Deiry, W.S. (1997). Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 14, 1047-1057.
50. Spencer, T.E., Jenster, G., Burcin, M.M., Allis, C.D., Zhou, J., Mizzen, C.A., McKenna, N.J., Onate, S.A., Tsai, S.Y., Tsai, M. J., and O'Malley, B. (1997). Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389, 194-198.
51. Talis, A.L., Huibregtse, J.M., and Howley, P.M. (1998). The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 273, 6439-6445.
52. Thomas, A., and White, E. (1998). Suppression of the p300-dependent mdm2 negative-feed back loop induces the p53 apoptotic function. Genes Dev. 12, 1975-1985.
53. Wu, X., Bayle, J.H., Olson, D., and Levine, A.J. (1993). The p53-mdm2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132.
54. Yang, X., Ogryzko, V.V., Nishikawa, J., Howard, B.H., and Nakatani, Y. (1996). A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382, 319-324.
55. Yao, T.P., Ku, G., Zhou, N., Scully, R., and Livingston, D.M. (1996). The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc. Natl. Acad. Sci. USA 93, 10626-10631.
56. Zhan, Q., Carrier, F., and Fornace, A.J. (1993). Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol. Cell. Biol. 13, 4242-4250.
57. Zhang, Y., Xiong, Y., and Yarbrough, W.G. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734.